February 15, 2017

BioCanRX makes a major investment in Canadian biotherapeutics research

 

CAT-T

Biotherapeutics, a relatively new class of treatments, have shown great promise and are generating a lot of excitement in the cancer research community. These treatments harness the power of oncolytic viruses, cell therapies and antibodies to kill cancer. BioCanRX, Canada’s biotherapeutics research network, has announced $11 million in funding for 16 projects that will enable scientists across the country to bring their innovations to patients sooner.

Continue reading – BioCanRX makes a major investment in Canadian biotherapeutics research